Kane receives clinical, preclinical data for revyve

Dr. Robert Huizinga reports KANE BIOTECH PRESENTS REVYVE DATA AT DIABETIC FOOT AND SOUTHERN REGION BURN CONFERENCES Kane Biotech Inc. has received new clinical and preclinical data demonstrating the performance of its Food and Drug Administration-cleared revyve anti-microbial wound gel and revyve wound gel spray in both diabetic foot ulcer healing and burn wound infection control. The findings were recently presented at two major U.S. medical meetings: Diabetic Foot Conference, held Oct. 23 to Oct. 25 in Anaheim, Calif., and the Southern Region Burn Conference, held Oct. 30 to Nov. 2 in Charleston, S.C. Clinical data: outperforming the standard of care At DFCon 2025, Dr. Raymond Abdo, DPM (St. Louis Foot and Ankle Institute), and Dr. Peter Moyer, DPM (Foot & Ankle Institute of the Carolinas), presented data showing revyve achieved healing outcomes exceeding the current standard of care for diabetic foot ulcers: 97-per-cent average area reduction in four weeks, compared with the 40- to 50-per-cent benchmark; Complete wound closure within eight to 12 weeks in all cases across a multicentre series; Sustained infection control and reduced bacterial bioburden throughout healing. "The usage of revyve gel has helped my patient proceed with increased healing wounds by keeping bacteria and bioburden at bay for hard-to-heal ulcerations," said Dr. Abdo. "revyve is a great product for diabetic ulcers. It utilizes advanced skin healing technology to promote faster and more effective wound healing by managing biofilm. revyve has helped manage my diabetic patients with peripheral arterial disease, hemodialysis and elevated A1c," said Dr. Moyer. Rapid anti-microbial efficacy in burn care At the 2025 Southern Region Burn Conference, Dr. Mack Drake, DO, FACS (Burn and Reconstructive Centers of America), presented preclinical data demonstrated 99.99- to 99.9999-per-cent reduction in burn-associated pathogens within 30 minutes of application. Additionally, sustained anti-biofilm activity was seen for seven days. "revyve's ability to achieve up to a six-log reduction in microbial load within minutes while maintaining anti-biofilm protection for at least seven days represents a significant advancement in burn wound management -- reducing the frequency of dressing changes and helping ease the overall burden of care for patients," said Dr. Drake. These meeting results are part of the second pillar of Kane's three-pillar strategy to significantly impact wound care in the United States: Conduct a U.S.-based case series demonstrating the clinical use of revyve; Report data at leading U.S. wound and burn care meetings; Rebuild the U.S. distributor and sales agent network. "These findings underscore revyve's ability to improve upon the standard of care in both diabetic foot and burn management," said Dr. Robert Huizinga, interim chief executive officer of Kane Biotech. "revyve's anti-biofilm and anti-microbial technology continues to demonstrate its potential to transform wound healing outcomes." About Kane Biotech Inc. Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, which results in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve anti-microbial wound gel and revyve anti-microbial wound gel spray are U.S. FDA 510(k) cleared. revyve anti-microbial wound gel is Health Canada approved. We seek Safe Harbor.